SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD

Overview

SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD is an active pharmaceutical ingredient (API) supplier with 23 active FDA Type II Drug Master Files, covering BALOXAVIR MARBOXIL; BIVALIRUDIN; CAGRILINTIDE; CETRORELIX ACETATE; DESMOPRESSIN ACETATE; DMT-2'FLUORO-DA(BZ) AMIDITE.

API / Drug Master Files

SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD holds 23 active (26 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• CAGRILINTIDEActive2026-03-26
• RETATRUTIDEActive2026-03-19
• SEMAGLUTIDE (SEMI-SYNTHETIC)Active2025-12-29
• RISDIPLAM INTERMEDIATE (CAS NO.: 2133298-74-3)Active2025-12-11
• SEMAGLUTIDEActive2025-12-01
• DMT-2'FLUORO-DA(BZ) AMIDITEActive2025-10-29
• ICOTROKINRAActive2025-08-29
• ORFORGLIPRONActive2025-04-27
• BALOXAVIR MARBOXILActive2025-04-18
• ELACESTRANT DIHYDROCHLORIDEActive2025-03-26
• RISDIPLAMActive2024-09-23
• TIRZEPATIDEActive2024-02-06
• DESMOPRESSIN ACETATEActive2023-01-16
• FULVESTRANT INTERMEDIATE (CAS NO.: 875573-66-3)Active2022-09-01
• SEMAGLUTIDEActive2021-11-01

Showing 15 of 26 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to SINOPEP-ALLSINO BIOPHARMACEUTICAL CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.